RU2008108216A - Фармацевтические дозированные формы и составы, содержащие лекозотан - Google Patents
Фармацевтические дозированные формы и составы, содержащие лекозотан Download PDFInfo
- Publication number
- RU2008108216A RU2008108216A RU2008108216/14A RU2008108216A RU2008108216A RU 2008108216 A RU2008108216 A RU 2008108216A RU 2008108216/14 A RU2008108216/14 A RU 2008108216/14A RU 2008108216 A RU2008108216 A RU 2008108216A RU 2008108216 A RU2008108216 A RU 2008108216A
- Authority
- RU
- Russia
- Prior art keywords
- max
- lecosotan
- patients
- patient
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71541705P | 2005-09-09 | 2005-09-09 | |
| US60/715,417 | 2005-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008108216A true RU2008108216A (ru) | 2009-10-20 |
Family
ID=37836444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008108216/14A RU2008108216A (ru) | 2005-09-09 | 2006-09-06 | Фармацевтические дозированные формы и составы, содержащие лекозотан |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1928863A2 (ko) |
| JP (1) | JP2009507850A (ko) |
| KR (1) | KR20080043855A (ko) |
| CN (1) | CN101258146A (ko) |
| AR (1) | AR058033A1 (ko) |
| AU (1) | AU2006287543A1 (ko) |
| BR (1) | BRPI0615771A2 (ko) |
| CA (1) | CA2620491A1 (ko) |
| CR (1) | CR9800A (ko) |
| EC (1) | ECSP088236A (ko) |
| GT (1) | GT200600403A (ko) |
| IL (1) | IL189827A0 (ko) |
| NO (1) | NO20081100L (ko) |
| PE (1) | PE20070334A1 (ko) |
| RU (1) | RU2008108216A (ko) |
| TW (1) | TW200800198A (ko) |
| WO (1) | WO2007030589A2 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| CN101553217A (zh) | 2005-07-06 | 2009-10-07 | 塞普拉科公司 | 艾司佐匹克隆与反式4－(3,4－二氯苯基)－1,2,3,4－四氢－n－甲基－1－萘胺或反式4－(3,4－二氯苯基)－1,2,3,4－四氢－1－萘胺的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法 |
| CN102573823B (zh) * | 2009-05-13 | 2015-01-07 | 桑诺维恩药品公司 | 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287066B6 (sk) * | 2000-09-29 | 2009-11-05 | Solvay Pharmaceuticals B. V. | Farmaceutická formulácia s predĺženým uvoľňovaním a spôsob jej prípravy |
| GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
| US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
| JP2008531694A (ja) * | 2005-03-01 | 2008-08-14 | ワイス | 結晶性および非晶性４−シアノ−ｎ−｛（２ｒ）−２−［４−（２，３−ジヒドロ−ベンゾ［１，４］ジオキシン−５−イル）−ピペラジン−１−イル］−プロピル｝−ｎ−ピリジン−２−イル−ベンズアミド塩酸塩 |
-
2006
- 2006-09-06 KR KR1020087007106A patent/KR20080043855A/ko not_active Application Discontinuation
- 2006-09-06 EP EP06790193A patent/EP1928863A2/en not_active Withdrawn
- 2006-09-06 GT GT200600403A patent/GT200600403A/es unknown
- 2006-09-06 AU AU2006287543A patent/AU2006287543A1/en not_active Abandoned
- 2006-09-06 CN CNA2006800328607A patent/CN101258146A/zh active Pending
- 2006-09-06 WO PCT/US2006/034813 patent/WO2007030589A2/en active Application Filing
- 2006-09-06 CA CA002620491A patent/CA2620491A1/en not_active Abandoned
- 2006-09-06 AR ARP060103880A patent/AR058033A1/es unknown
- 2006-09-06 TW TW095132852A patent/TW200800198A/zh unknown
- 2006-09-06 JP JP2008530186A patent/JP2009507850A/ja not_active Withdrawn
- 2006-09-06 BR BRPI0615771-8A patent/BRPI0615771A2/pt not_active Application Discontinuation
- 2006-09-06 PE PE2006001076A patent/PE20070334A1/es not_active Application Discontinuation
- 2006-09-06 RU RU2008108216/14A patent/RU2008108216A/ru not_active Application Discontinuation
-
2008
- 2008-02-28 IL IL189827A patent/IL189827A0/en unknown
- 2008-03-03 NO NO20081100A patent/NO20081100L/no not_active Application Discontinuation
- 2008-03-04 EC EC2008008236A patent/ECSP088236A/es unknown
- 2008-03-07 CR CR9800A patent/CR9800A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080043855A (ko) | 2008-05-19 |
| IL189827A0 (en) | 2008-11-03 |
| WO2007030589A3 (en) | 2007-11-01 |
| BRPI0615771A2 (pt) | 2011-05-24 |
| WO2007030589A2 (en) | 2007-03-15 |
| NO20081100L (no) | 2008-06-03 |
| CA2620491A1 (en) | 2007-03-15 |
| AU2006287543A1 (en) | 2007-03-15 |
| TW200800198A (en) | 2008-01-01 |
| AR058033A1 (es) | 2008-01-23 |
| CN101258146A (zh) | 2008-09-03 |
| JP2009507850A (ja) | 2009-02-26 |
| GT200600403A (es) | 2007-09-19 |
| ECSP088236A (es) | 2008-04-28 |
| EP1928863A2 (en) | 2008-06-11 |
| PE20070334A1 (es) | 2007-05-08 |
| CR9800A (es) | 2008-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| US8772309B2 (en) | Pharmaceutical formulation of apomorphine for buccal administration | |
| US20080096800A1 (en) | Rapid mucosal gel or film insulin compositions | |
| US20080085298A1 (en) | Rapid Mucosal Gel or Film Insulin Compositions | |
| BR112019010466A2 (pt) | sistema terapêutico transdérmico contendo asenapina | |
| JP2012529523A (ja) | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 | |
| EP2635269B1 (en) | A combination composition | |
| TWI763632B (zh) | 用於重症治療時之鎮靜方法及非口服調配物 | |
| US20160256529A1 (en) | Combination therapy | |
| US20210128507A1 (en) | Formulation for use in a method of treatment of pain | |
| US20210244657A1 (en) | Edaravone pharmaceutical composition | |
| US20110257149A1 (en) | Formulation for oral transmucosal administration of lipid-lowering drugs | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| RU2008108216A (ru) | Фармацевтические дозированные формы и составы, содержащие лекозотан | |
| JP2010538066A5 (ko) | ||
| KR100709528B1 (ko) | 혈당콘트롤용 의약조성물 | |
| CN113557016A (zh) | 衣壳组装调节剂固体配制品 | |
| US20220288024A1 (en) | Methods of treating bacterial infections | |
| JP2009507850A5 (ko) | ||
| US20060167100A1 (en) | Orodispersible pharmaceutical composition of an antithrombotic compound | |
| US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
| US20230028539A1 (en) | Pharmaceutical composition, complementary kit and application thereof | |
| US11903945B2 (en) | Methods of treating antipsychotic-induced weight gain with miricorilant | |
| US20210052608A1 (en) | Methods of treating bacterial infections with minocycline | |
| MX2015003810A (es) | Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20091012 |